HRP20210255T1 - Postupak priprave derivata karbamoilpiridona i međuprodukata - Google Patents

Postupak priprave derivata karbamoilpiridona i međuprodukata Download PDF

Info

Publication number
HRP20210255T1
HRP20210255T1 HRP20210255TT HRP20210255T HRP20210255T1 HR P20210255 T1 HRP20210255 T1 HR P20210255T1 HR P20210255T T HRP20210255T T HR P20210255TT HR P20210255 T HRP20210255 T HR P20210255T HR P20210255 T1 HRP20210255 T1 HR P20210255T1
Authority
HR
Croatia
Prior art keywords
intermediates
preparing
carbamoylpyridone derivatives
carbamoylpyridone
derivatives
Prior art date
Application number
HRP20210255TT
Other languages
English (en)
Inventor
Huan Wang
Steven N Goodman
Douglas Mans
Matthew Kowalski
Original Assignee
Viiv Healthcare Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Company filed Critical Viiv Healthcare Company
Publication of HRP20210255T1 publication Critical patent/HRP20210255T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Claims (2)

1. Spoj formule (IV) [image] , naznačen time što je R alkil, aril ili benzil.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je 1-[2,2-bis(metiloksi)etil]-5-(metiloksi)-6-[(metiloksi)karbonil]-4-okso-1,4-dihidro-3-piridinkarboksilna kiselina.
HRP20210255TT 2010-03-23 2021-02-15 Postupak priprave derivata karbamoilpiridona i međuprodukata HRP20210255T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31642110P 2010-03-23 2010-03-23
EP17165935.2A EP3260457B1 (en) 2010-03-23 2011-03-22 Process for preparing carbamoylpyridone derivatives and intermediates

Publications (1)

Publication Number Publication Date
HRP20210255T1 true HRP20210255T1 (hr) 2021-04-02

Family

ID=44673569

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20170961TT HRP20170961T1 (hr) 2010-03-23 2017-06-26 Postupak dobivanja karbamoilpiridonskih derivata i međuprodukata
HRP20210255TT HRP20210255T1 (hr) 2010-03-23 2021-02-15 Postupak priprave derivata karbamoilpiridona i međuprodukata

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20170961TT HRP20170961T1 (hr) 2010-03-23 2017-06-26 Postupak dobivanja karbamoilpiridonskih derivata i međuprodukata

Country Status (19)

Country Link
US (9) US8889877B2 (hr)
EP (2) EP3260457B1 (hr)
JP (1) JP5490305B2 (hr)
KR (1) KR101440278B1 (hr)
CN (1) CN102933080B (hr)
CY (2) CY1119143T1 (hr)
DK (2) DK2549870T3 (hr)
ES (2) ES2632346T3 (hr)
HR (2) HRP20170961T1 (hr)
HU (2) HUE033863T2 (hr)
LT (2) LT2549870T (hr)
ME (1) ME02703B (hr)
PL (2) PL2549870T3 (hr)
PT (2) PT3260457T (hr)
RS (2) RS61436B1 (hr)
SG (1) SG184186A1 (hr)
SI (2) SI3260457T1 (hr)
TW (1) TWI582097B (hr)
WO (1) WO2011119566A1 (hr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5586602B2 (ja) 2008-07-25 2014-09-10 ビーブ・ヘルスケア・カンパニー 化合物
KR101682058B1 (ko) 2008-12-11 2016-12-02 비이브 헬쓰케어 컴퍼니 카르바모일피리돈 ｈｉｖ 인테그라제 억제제를 위한 제조방법 및 중간체
AU2009325128B2 (en) 2008-12-11 2015-01-29 Shionogi & Co., Ltd. Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
TWI582097B (zh) 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
ES2608377T3 (es) * 2010-08-05 2017-04-10 Shionogi & Co., Ltd. Procedimiento de preparación de un compuesto que tiene actividad inhibidora de la integrasa del HIV
CA3012242C (en) 2012-12-21 2021-11-02 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US9573965B2 (en) 2013-02-19 2017-02-21 Aurobindo Pharma Ltd Process for the preparation of Dolutegravir
NO2865735T3 (hr) 2013-07-12 2018-07-21
JP6411491B2 (ja) 2013-07-12 2018-10-24 ギリアード サイエンシス インコーポレーテッド 多環式カルバモイルピリドン化合物およびｈｉｖ感染症を処置するためのその使用
WO2015019310A1 (en) * 2013-08-07 2015-02-12 Mylan Laboratories Ltd Process for the preparation of dolute-gravir and intermediates thereof
US9808428B2 (en) 2014-01-14 2017-11-07 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
US9856271B2 (en) 2014-01-21 2018-01-02 Laurus Labs Limited Process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
WO2015177537A1 (en) * 2014-05-20 2015-11-26 Cipla Limited Process for preparing polycyclic carbamoyl pyridone derivatives and intermediates thereof
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (hr) 2014-06-20 2018-06-23
WO2016057866A1 (en) 2014-10-09 2016-04-14 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
CN104557686A (zh) * 2014-12-29 2015-04-29 徐俊烨 一种吡啶酮类化合物的合成方法
EP3045461A1 (en) 2015-01-16 2016-07-20 LEK Pharmaceuticals d.d. Processes for preparing dolutegravir and analogues thereof
EP3253767A2 (en) * 2015-02-06 2017-12-13 Mylan Laboratories Ltd. Processes for the preparation of dolute-gravir
AU2016244035B2 (en) 2015-04-02 2018-11-01 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
WO2017109649A1 (en) 2015-12-21 2017-06-29 Lupin Limited Process for the preparation of hiv integrase inhibitors
WO2017205585A1 (en) * 2016-05-27 2017-11-30 Viiv Healthcare Company Combinations and uses treatments thereof
CN106565747A (zh) * 2016-11-10 2017-04-19 顾世海 一种制备度鲁特韦的新方法
JOP20190130A1 (ar) 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
WO2018149608A1 (en) 2017-02-16 2018-08-23 Sandoz Ag Crystalline forms of cabotegravir sodium
EP3363802B1 (en) 2017-02-16 2019-11-20 Sandoz AG Crystalline form of cabotegravir sodium
US11839623B2 (en) 2018-01-12 2023-12-12 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof
WO2019159199A1 (en) * 2018-02-16 2019-08-22 Cipla Limited Continues flow process for the preparation of active pharmaceutical ingredients - polycyclic carbamoyl pyridone derivatives and intermediates thereof
WO2019199756A1 (en) 2018-04-09 2019-10-17 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof
WO2020012408A2 (en) 2018-07-12 2020-01-16 Laurus Labs Limited A process for purification of protected polycyclic carbamoylpyridone derivatives
CN109438334A (zh) * 2018-10-29 2019-03-08 南京杰运医药科技有限公司 一种度鲁特韦中间体的合成方法
CN109293675A (zh) * 2018-11-19 2019-02-01 遵义医学院 一种改进的度鲁特韦制备工艺
CN110128448A (zh) * 2019-05-22 2019-08-16 博诺康源(北京)药业科技有限公司 一种度鲁特韦原料及中间体中非对映异构体杂质的合成方法
RU2717101C1 (ru) 2019-06-03 2020-03-18 Андрей Александрович Иващенко Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
US20200398978A1 (en) 2019-06-20 2020-12-24 Bell Helicopter Textron Inc. Low-drag rotor blade extension
US11248005B2 (en) 2019-07-08 2022-02-15 Lupin Limited Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor
CN111620891B (zh) * 2020-05-27 2023-07-14 上海启讯医药科技有限公司 一种多替拉韦关键中间体溶剂化物多晶型物及其制备方法和用途
CN112500336A (zh) * 2020-12-15 2021-03-16 内蒙古永太化学有限公司 一种度鲁特韦母核中间体的制备方法
CN115572257A (zh) * 2021-06-21 2023-01-06 江西帝劢药业有限公司 一种吡啶酮类化合物的合成方法
CN113816972B (zh) * 2021-11-17 2022-03-18 奥锐特药业(天津)有限公司 一种hiv抑制剂的制备方法及其中间体晶型
CN114605437A (zh) * 2022-04-01 2022-06-10 遵义医科大学 连续一锅法制备三个替拉韦药物的合成工艺

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4524149A (en) 1982-03-15 1985-06-18 Sterling Drug Inc. 5-Alkanoyl-6-alkyl-2(1H)-pyridinones, their preparation and their cardiotonic use
US4769380A (en) 1983-04-29 1988-09-06 Merrell Dow Pharmaceuticals Inc. Cardiotonic 5-benzoyl-1,2-dihydro-2-oxo-3-pyridinecarboxylates
US4603144A (en) 1984-08-16 1986-07-29 G. D. Searle & Co. Kojic acid ether-ester derivatives
US4735964A (en) 1984-08-16 1988-04-05 G. D. Searle & Co. Kojic acid ether-ester derivatives
US4812474A (en) 1984-08-16 1989-03-14 G. D. Searle & Co. Kojic acid ether-ester derivatives
GB2280435A (en) 1993-07-29 1995-02-01 Merck & Co Inc Anti-viral agent
DE59611243D1 (de) 1995-09-29 2005-08-11 Novartis Ag Hydroxypyridinone
GB9711093D0 (en) 1997-05-29 1997-07-23 British Tech Group Novel orally active iron (III) chelators
US6452008B2 (en) 1998-02-25 2002-09-17 Sumitomo Pharmaceuticals Company, Limited Pyridone derivatives and process for preparing the same
US7256286B2 (en) 1999-11-30 2007-08-14 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
WO2003013528A1 (en) * 2001-08-02 2003-02-20 Neurocrine Biosciences, Inc. Substituted pyridin-4-ones and their use as gonadotropin-releasing hormone receptor antagonists.
US6426418B1 (en) 2001-11-02 2002-07-30 Apotex, Inc. Processes for the manufacturing of 3-hydroxy-N,1,6-trialkyl-4-oxo-1,4-dihydropyridine-2-carboxamide
CA2379370A1 (en) 2002-03-28 2003-09-28 Apotex Inc. Carboxylic acid derivatives of 3-hydroxy-4-oxo-1,4-dihydropyridine as iron chelators
CA2498111A1 (en) 2002-09-11 2004-03-25 Merck & Co., Inc. Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors
AU2003301439A1 (en) 2002-10-16 2004-05-04 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
DE10349500A1 (de) 2003-10-23 2005-06-02 Bayer Cropscience Ag Verfahren zum Herstellen von 2-Dihalogenacyl-3-amino-acrylsäureestern und 3-Dihalogenmethyl-pyrazol-4-carbonsäureestern
US7645292B2 (en) 2003-10-27 2010-01-12 Boston Scientific Scimed, Inc. Vaso-occlusive devices with in-situ stiffening elements
AU2005227258A1 (en) 2004-03-09 2005-10-06 Merck & Co., Inc. HIV integrase inhibitors
WO2005087766A1 (en) 2004-03-09 2005-09-22 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Hiv integrase inhibitors
CA2562713A1 (en) 2004-04-14 2005-12-15 Gilead Sciences, Inc. Phosphonate analogs of hiv integrase inhibitor compounds
WO2006030807A1 (ja) 2004-09-15 2006-03-23 Shionogi & Co., Ltd. Ｈｉｖインテグラーゼ阻害活性を有するカルバモイルピリドン誘導体
CA2488034C (en) 2004-11-19 2009-10-06 Apotex Inc. Process for the manufacture of 3-hydroxy-n-alkyl-1-cycloalkyl-6-alkyl-4-oxo-1,4-dihydropyridine-2-carboxamide and its related analogues
JP5068663B2 (ja) 2004-12-16 2012-11-07 ジェネラル・ケーブル・テクノロジーズ・コーポレーション フィラーエレメントを有する異質のクロストークが軽減された電気ケーブル
CA2634499A1 (en) 2004-12-23 2006-06-29 Virochem Pharma Inc. Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase
WO2006088173A1 (ja) 2005-02-21 2006-08-24 Shionogi & Co., Ltd. Ｈｉｖインテグラーゼ阻害活性を有する２環性カルバモイルピリドン誘導体
UA96568C2 (en) * 2005-04-28 2011-11-25 Глаксосмиткляйн Ллк Polycyclic carbamoyl pyridone derivative as hiv-integrase inhibitor
NZ562339A (en) * 2005-04-28 2011-01-28 Smithkline Beecham Corp Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
TW200716632A (en) 2005-05-16 2007-05-01 Gilead Sciences Inc Integrase inhibitor compounds
JP2006342115A (ja) 2005-06-10 2006-12-21 Shionogi & Co Ltd Ｈｉｖインテグラーゼ阻害活性を有する多環性化合物
KR101170120B1 (ko) * 2005-07-27 2012-07-31 삼성전자주식회사 비안경식 3차원 디스플레이 장치
EP1762250A1 (en) 2005-09-12 2007-03-14 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine
WO2007049676A1 (ja) 2005-10-27 2007-05-03 Kao Corporation 脱酸素剤、脱酸素剤中間体、脱酸素剤複合体及びその製造方法
TW200800988A (en) 2005-10-27 2008-01-01 Shionogi & Amp Co Ltd Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
EP2114898A2 (en) 2007-02-16 2009-11-11 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
JP5586602B2 (ja) * 2008-07-25 2014-09-10 ビーブ・ヘルスケア・カンパニー 化合物
WO2010011819A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
SI2320908T1 (sl) 2008-07-25 2014-05-30 Viiv Healthcare Company Predzdravila dolutegravirja
AU2009325128B2 (en) 2008-12-11 2015-01-29 Shionogi & Co., Ltd. Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
KR101682058B1 (ko) 2008-12-11 2016-12-02 비이브 헬쓰케어 컴퍼니 카르바모일피리돈 ｈｉｖ 인테그라제 억제제를 위한 제조방법 및 중간체
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
TWI582097B (zh) 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
ES2608377T3 (es) 2010-08-05 2017-04-10 Shionogi & Co., Ltd. Procedimiento de preparación de un compuesto que tiene actividad inhibidora de la integrasa del HIV

Also Published As

Publication number Publication date
JP5490305B2 (ja) 2014-05-14
RS56072B1 (sr) 2017-10-31
HUE033863T2 (en) 2018-01-29
EP2549870A1 (en) 2013-01-30
RS61436B1 (sr) 2021-03-31
US20190100532A1 (en) 2019-04-04
JP2013522366A (ja) 2013-06-13
US20170204117A1 (en) 2017-07-20
CY1119143T1 (el) 2018-02-14
US20150329559A1 (en) 2015-11-19
ES2632346T3 (es) 2017-09-12
PL2549870T3 (pl) 2017-12-29
LT2549870T (lt) 2017-07-10
US9938296B2 (en) 2018-04-10
PL3260457T3 (pl) 2021-06-28
SI3260457T1 (sl) 2021-04-30
KR101440278B1 (ko) 2014-10-30
US20180186811A1 (en) 2018-07-05
US20190106435A1 (en) 2019-04-11
EP3260457A1 (en) 2017-12-27
US9643981B2 (en) 2017-05-09
DK3260457T3 (da) 2021-02-22
US9120817B2 (en) 2015-09-01
US10647728B2 (en) 2020-05-12
US20130172551A1 (en) 2013-07-04
ES2856020T3 (es) 2021-09-27
CN102933080A (zh) 2013-02-13
US8889877B2 (en) 2014-11-18
LT3260457T (lt) 2021-04-26
CY1123958T1 (el) 2022-05-27
EP3260457B1 (en) 2020-12-02
SG184186A1 (en) 2012-10-30
US20190100533A1 (en) 2019-04-04
TWI582097B (zh) 2017-05-11
TW201202253A (en) 2012-01-16
KR20130026433A (ko) 2013-03-13
CN102933080B (zh) 2015-05-27
HRP20170961T1 (hr) 2017-09-22
EP2549870B1 (en) 2017-04-19
US10233196B2 (en) 2019-03-19
WO2011119566A1 (en) 2011-09-29
EP2549870A4 (en) 2013-10-16
SI2549870T1 (sl) 2017-07-31
PT2549870T (pt) 2017-07-05
US20180186812A1 (en) 2018-07-05
US20150057444A1 (en) 2015-02-26
HUE052848T2 (hu) 2021-05-28
DK2549870T3 (en) 2017-07-03
PT3260457T (pt) 2021-03-03
US10654870B2 (en) 2020-05-19
ME02703B (me) 2017-10-20
US10174051B2 (en) 2019-01-08
US10654871B2 (en) 2020-05-19

Similar Documents

Publication Publication Date Title
HRP20210255T1 (hr) Postupak priprave derivata karbamoilpiridona i međuprodukata
HRP20171028T1 (hr) Indolski i indazolski spojevi koji aktiviraju ampk
HRP20200538T1 (hr) Derivati pirimidina za liječenje virusnih infekcija
WO2014028589A3 (en) 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
CA2826751C (en) Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
MD20140072A2 (ro) Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin
PH12014502524B1 (en) Carboxylic acid compounds
WO2011156610A3 (en) Quinoline and isoquinoline derivatives as inhibitors of hepatitis c virus
HRP20221304T1 (hr) Kombinacija koja sadrži inhibitor mek i inhibitor b-raf
PH12015501452A1 (en) Novel quinolone derivatives
MD4490C1 (ro) Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin
EA201591390A1 (ru) Пиразол[1,5-a]пиримидины для противовирусного лечения
MX2016006336A (es) Compuestos pirazolopirimidina.
BR112014010765A2 (pt) Cristal de sal de ácido carboxílico - 7 {(3s, 4s) -3- [ciclopropilamino] -4- fluoropirolidina-1- ila-}6 fluor-1-(2-fluor-etila)-8-metoxi-4- oxo-1,4-dihidroquinole-3
GEP201706774B (en) Heterocyclyl compounds
FR2957914B1 (fr) Nouveau procede de preparation de silices precipitees contenant de l'aluminium
AU2018236805B2 (en) Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
PH12015500457A1 (en) Alkoxy pyrazoles as soluble guanylate cyclase activators
WO2009115562A3 (en) Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts
CA2920410C (en) Thienopiperidine derivative and use thereof
WO2013109388A3 (en) 1,5-naphthyridine derivatives and melk inhibitors containing the same
MX2014005075A (es) Formulaciones de sal de meglumina del acido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxilico.
WO2014036502A8 (en) Tetracycline compounds
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
CA2922375C (en) Alpha-tea salt forms: compositions and uses for treating disease